Table 1.
Quantitation of Tumor Volume (cm3), AR Expression (AR MOD and %AR Positivity), Tumor Cellular Proliferation (%Ki-67 Positivity), and PSA Serum Levels (ng/ml) and Tissue Expression (%PSA Positivity) Measured in Androgen-Stimulated, Androgen-Deprived and Recurrent CWR22 Tumors*
| Days after castration | No. of tumors | Tumor volume | AR MOD | %AR positivity | %Ki-67 positivity | Serum PSA | %PSA positivity |
|---|---|---|---|---|---|---|---|
| intact CWR22 | 12 | 1.11 ± 0.94† | 0.26 ± 0.01‡ | 98.5 ± 0.2 | 73.5 ± 4.4 | 246.7 ± 55.3† | 17.4 ± 3.6 |
| Day 1 | 2 | 0.15 ± 0.10 | 28.5 ± 7.4 | 56.9 ± 7.5 | 3.4 ± 1.0 | ||
| Day 2 | 4 | 0.81 ± 0.09 | 0.16 ± 0.08 | 2.3 ± 5.5 | 26.1 ± 5.6 | 169.0 ± 53.7 | 5.5 ± 2.8 |
| Day 4 | 2 | 0.11 ± 0.09 | 9.9 ± 8.6 | 9.4 ± 8.1 | 4.8 ± 1.1 | ||
| Day 6 | 6 | 0.72 ± 0.49 | 0.15 ± 0.06 | 62.7 ± 4.8§ | 0.8 ± 0.5 | 109.9 ± 76.3 | 5.6 ± 1.5 |
| Day 12 | 6 | 0.81 ± 0.27 | 0.17 ± 0.06 | 70.9 ± 4.9§ | 0.3 ± 0.3 | 18.8 ± 10.8 | 0.8 ± 0.9 |
| Day 32 | 4 | 0.64 ± 0.25 | 0.17 ± 0.11 | 70.4 ± 7.3§ | 0.1 ± 0.3 | 5.6 ± 4.1 | 0.6 ± 0.3 |
| Day 64 | 2 | 0.15 ± 0.05 | 71.7 ± 12.2§ | 0.4 ± 0.2 | 1.1 ± 0.1 | ||
| Day 90 | 4 | 0.64 ± 0.30 | 0.17 ± 0.05 | 73.4 ± 6.5§ | 0.8 ± 0.5 | 11.1 ± 1.8 | 1.5 ± 0.7 |
| Day 120 | 4 | 0.78 ± 0.37 | 0.17 ± 0.03 | 72.3 ± 8.4§ | 3.3 ± 1.2 | 21.3 ± 4.1∥ | 3.4 ± 0.1∥ |
| Recurrent CWR22 | 12 | 1.63 ± 0.38 | 0.26 ± 0.01¶ | 72.1 ± 7.6§ | 49.1 ± 7.4¶ | 261.5 ± 123.0¶ | 7.2 ± 1.3¶ |
*AR mean optical density (MOD), percent AR positivity, percent Ki-67 positivity, serum PSA level, and percent PSA positivity at all time points after castration decreased significantly (P < 0.01) compared to intact CWR22 except no significant differences were found for AR MOD in recurrent CWR22 and percent AR positivity on days 90 and 120 after castration compared to day 0 (P > 0.05).
†Tumor volume and serum PSA is described by mean ± SD and therefore the data for time points containing only two measurements were not presented.
‡The image analysis data for all nuclei for all tumors at each time point is described by mean ± SD. Each tumor is represented by 20 images containing 200 to 250 nuclei for AR and 400 to 500 nuclei for Ki-67.
§Percent AR positivity on days 6, 12, 32, 64, 90, and 120 after castration and upon recurrence increased significantly (P < 0.001) compared to days 1, 2, and 4 after castration.
¶Recurrent CWR22 showed a significant increase in AR MOD, percent Ki-67 positivity, serum PSA level, and percent PSA positivity compared to time points after castration (P < 0.01).
∥Serum PSA level and percent PSA positivity on day 120 after castration were significantly higher than on day 90 after castration (P < 0.05).